Beam Therapeutics Inc. (BEAM) stock forecast and price target
Price $22.83 · data as of November 13, 2026
12-month price target
Average target$49.85
Upside / downside+118.3%
Analysts13
ConsensusStrong buy
Low $26.00Average $49.85High $80.00
Gold marker: average target · white marker: today’s price ($22.83)
Analyst ratings
Strong buy 1Buy 12Hold 2Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-4.53 | −459.6% | $39M |
| Next fiscal year ends December 31, 2027 | $-5.01 | −10.6% | $31M |
| Next quarter ends December 31, 2026 | $-1.22 | −152.4% | $6M |
| Quarter after ends March 31, 2027 | $-1.24 | −36.3% | $400000 |
Consensus of the analysts covering Beam Therapeutics, updated daily. In the last 30 days 0 estimates were raised and 10 lowered.
Frequently asked questions
What is the Beam Therapeutics stock price target?
The average 12-month target from 13 analysts is $49.85, 118.3% above the current price of $22.83 Targets range from $26.00 to $80.00.
Is Beam Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 12 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Beam Therapeutics expected to earn?
Analysts expect EPS of $-4.53 for the fiscal year ending December 31, 2026 and $-5.01 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.